Emergent BioSolutions (EBS) Receivables - Other (2017 - 2026)

Emergent BioSolutions' Receivables - Other history runs 10 years deep, the most recent figure standing at $18.3 million for Q1 2026.

• In Q1 2026, Receivables - Other fell 40.78% year-over-year to $18.3 million; the TTM figure through Mar 2026 stood at $18.3 million (down 40.78% YoY), while the FY2025 annual figure was $18.2 million, down 7.14% from the prior year.
• Receivables - Other was $18.3 million for Q1 2026 at Emergent BioSolutions, up from $18.2 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $82.5 million in Q2 2024 to a low of $18.2 million in Q4 2025.
• Historically, Receivables - Other has averaged $43.4 million across 5 years, with a median of $49.8 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Receivables - Other soared 59.27% in 2024, then tumbled 72.24% in 2025.
• A 5-year view of Receivables - Other shows it stood at $57.2 million in 2022, then retreated by 10.14% to $51.4 million in 2023, then tumbled by 61.87% to $19.6 million in 2024, then decreased by 7.14% to $18.2 million in 2025, then gained by 0.55% to $18.3 million in 2026.
• The last three Receivables - Other figures came in at $18.3 million (Q1 2026), $18.2 million (Q4 2025), and $19.3 million (Q3 2025), per Business Quant data.